(Reuters) – A European regulator of health stated on Thursday that they were assessing a market authorisation application from GSK-Vir Biotechnology to treat COVID-19 with monoclonal antibodies. They could provide their opinion in two months.

Sotrovimab was already subject to a quick review by the European Medicines Agency, (EMA). GSK’s application for the drug makes it the fourth currently under EU lenses.

It is approved for use as an emergency medication in the United States. This will prevent COVID-19’s mild to moderate symptoms from becoming worsening. While the EMA granted its consent for use in member countries, Thursday’s request would be considered for approval by the EU.

It is not like oral options offered by Merck Pfizer Sotrovimab (NYSE:) is administered via infusion. Monoclonal antibody drugs, such as sotrovimab from the lab mimicking our natural defenses, are a group of drugs called Sotrovimab.

GSK and Vir announced last week that the anti-body treatment worked when administered as a shot in one’s arm, which could make it more convenient.

Recent support by the EMA for similar anti-inflammatories from American-Swiss Partners Regeneron-Roche, and one from South Korea’s Celltrion was given to the region as part of its efforts to defend itself against surging cases.